Fig. 2
From: Innate immunity based cancer immunotherapy: B16-F10 murine melanoma model
Immunotherapy of melanoma B16-F10 based on the synergy of R-848 and mannan-BAM. The experimental design was the same as described in Fig. 1. Six mice were used per group. The composition of therapeutic mixture was: 0.5 mg R-848, HCl form/ml PBS, 0.5 mg R-848, HCl form/ml 0.2 mM mannan-BAM in PBS, 0.2 mM mannan-BAM in PBS, PBS. a The effect of therapy on tumor growth. * P ≤ 0.05 * * P ≤ 0.005 * * * P ≤ 0.0005 compared to control (PBS). o P ≤ 0.05 o o P ≤ 0.005 o o o P ≤ 0.001 compared to mannan-BAM. b Survival analysis. a – R-848, b – R-848 + mannan-BAM, c – mannan-BAM, d- PBS (control)